PMID- 34525791
OWN - NLM
STAT- MEDLINE
DCOM- 20221227
LR  - 20221227
IS  - 2233-6087 (Electronic)
IS  - 2233-6079 (Print)
IS  - 2233-6079 (Linking)
VI  - 46
IP  - 2
DP  - 2022 Mar
TI  - SUDOSCAN in Combination with the Michigan Neuropathy Screening Instrument Is an 
      Effective Tool for Screening Diabetic Peripheral Neuropathy.
PG  - 319-326
LID - 10.4093/dmj.2021.0014 [doi]
AB  - BACKGROUND: Screening for diabetic peripheral neuropathy (DPN) is important to 
      prevent severe foot complication, but the detection rate of DPN is 
      unsatisfactory. We investigated whether SUDOSCAN combined with Michigan 
      Neuropathy Screening Instrument (MNSI) could be an effective tool for screening 
      for DPN in people with type 2 diabetes mellitus (T2DM) in clinical practice. 
      METHODS: We analysed the data for 144 people with T2DM without other cause of 
      neuropathy. The presence of DPN was confirmed according to the Toronto Consensus 
      criteria. Electrochemical skin conductance (ESC) of the feet was assessed using 
      SUDOSCAN. We compared the discrimination power of following methods, MNSI only 
      vs. SUDOSCAN only vs. MNSI plus SUDOSCAN vs. MNSI plus 10-g monofilament test. 
      RESULTS: Confirmed DPN was detected in 27.8% of the participants. The optimal 
      cut-off value of feet ESC to distinguish DPN was 56 muS. We made the DPN screening 
      scores using the corresponding odds ratios for MNSI-Questionnaire, MNSI-Physical 
      Examination, SUDOSCAN, and 10-g monofilament test. For distinguishing the 
      presence of DPN, the MNSI plus SUDOSCAN model showed higher areas under the 
      receiver operating characteristic curve (AUC) than MNSI only model (0.717 vs. 
      0.638, P=0.011), and SUDOSCAN only model or MNSI plus 10-g monofilament test 
      showed comparable AUC with MNSI only model. CONCLUSION: The screening model for 
      DPN that includes both MNSI and SUDOSCAN can detect DPN with acceptable 
      discrimination power and it may be useful in Korean patients with T2DM.
FAU - Oh, Tae Jung
AU  - Oh TJ
AD  - Department of Internal Medicine, Seoul National University College of Medicine, 
      Seoul, Korea.
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seongnam, Korea.
FAU - Song, Yoojung
AU  - Song Y
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seongnam, Korea.
FAU - Jang, Hak Chul
AU  - Jang HC
AD  - Department of Internal Medicine, Seoul National University College of Medicine, 
      Seoul, Korea.
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seongnam, Korea.
FAU - Choi, Sung Hee
AU  - Choi SH
AD  - Department of Internal Medicine, Seoul National University College of Medicine, 
      Seoul, Korea.
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seongnam, Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210916
PL  - Korea (South)
TA  - Diabetes Metab J
JT  - Diabetes & metabolism journal
JID - 101556588
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/complications
MH  - *Diabetic Neuropathies/diagnosis
MH  - Mass Screening/methods
MH  - Michigan/epidemiology
PMC - PMC8987688
OTO - NOTNLM
OT  - Diabetes mellitus, type 2
OT  - Diabetic neuropathies
OT  - Diagnostic screening programs
COIS- CONFLICTS OF INTEREST No potential conflict of interest relevant to this article 
      was reported.
EDAT- 2021/09/17 06:00
MHDA- 2022/04/09 06:00
PMCR- 2022/03/01
CRDT- 2021/09/16 04:00
PHST- 2021/01/27 00:00 [received]
PHST- 2021/06/13 00:00 [accepted]
PHST- 2021/09/17 06:00 [pubmed]
PHST- 2022/04/09 06:00 [medline]
PHST- 2021/09/16 04:00 [entrez]
PHST- 2022/03/01 00:00 [pmc-release]
AID - dmj.2021.0014 [pii]
AID - dmj-2021-0014 [pii]
AID - 10.4093/dmj.2021.0014 [doi]
PST - ppublish
SO  - Diabetes Metab J. 2022 Mar;46(2):319-326. doi: 10.4093/dmj.2021.0014. Epub 2021 
      Sep 16.